Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

3/5/25 4:05:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ASRT alert in real time by email

LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-646-307-1963. The call ID is 3278948.

A webcast replay of the call will be available approximately two hours after the call on Assertio's investor website.

About Assertio

Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs. Our focus is on supporting patients through marketing such products for oncology, neurology, and pain management. To learn more about Assertio, visit www.assertiotx.com.

Investor Contact

Matt Kreps

Darrow Associates Investor Relations

+1-214-597-8200

[email protected]

Get the next $ASRT alert in real time by email

Date	Price Target	Rating	Analyst
7/26/2024	$3.00	Buy	Maxim Group
7/3/2024	$4.00	Buy	H.C. Wainwright
11/7/2022	$7.00	Buy	Lake Street

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

Chat with this insight

Recent Analyst Ratings for
$ASRT

$ASRT
Leadership Updates

Live Leadership Updates

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

$ASRT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

$ASRT
SEC Filings

SEC Form S-8 filed by Assertio Holdings Inc.

Assertio Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by Assertio Holdings Inc.

$ASRT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO O'Grady Brendan P. converted options into 166,665 shares and covered exercise/tax liability with 49,416 shares, increasing direct ownership by 1,002% to 128,955 units (SEC Form 4)

EVP, General Counsel Schlessinger Sam converted options into 38,017 shares and covered exercise/tax liability with 14,958 shares, increasing direct ownership by 15% to 176,948 units (SEC Form 4)

Officer Schwichtenberg Paul converted options into 38,017 shares and covered exercise/tax liability with 16,840 shares, increasing direct ownership by 14% to 167,522 units (SEC Form 4)

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

Chat with this insight

Recent Analyst Ratings for $ASRT

$ASRT Leadership Updates

Live Leadership Updates

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

$ASRT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

$ASRT SEC Filings

SEC Form S-8 filed by Assertio Holdings Inc.

Assertio Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by Assertio Holdings Inc.

$ASRT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO O'Grady Brendan P. converted options into 166,665 shares and covered exercise/tax liability with 49,416 shares, increasing direct ownership by 1,002% to 128,955 units (SEC Form 4)

EVP, General Counsel Schlessinger Sam converted options into 38,017 shares and covered exercise/tax liability with 14,958 shares, increasing direct ownership by 15% to 176,948 units (SEC Form 4)

Officer Schwichtenberg Paul converted options into 38,017 shares and covered exercise/tax liability with 16,840 shares, increasing direct ownership by 14% to 167,522 units (SEC Form 4)

Recent Analyst Ratings for
$ASRT

$ASRT
Leadership Updates

$ASRT
Insider Purchases

$ASRT
SEC Filings

$ASRT
Insider Trading